All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The U. S. Food and Drug Administration (FDA) has granted orphan drug designation to AB8939 for the treatment of patients with acute myeloid leukemia (AML).1 AB8939 was shown to offer therapeutic benefit in refractory/relapsed AML.
AB8939 is a novel tubulin inhibitor which seems able to overcome drug resistance induced by P-glycoprotein (Pgp). It acts by binding to the colchicine-binding site of the beta-subunit of tubulin, leading to apoptosis via mitotic cell cycle arrest at the G2/M phase. Unlike vinca alkaloids (e.g. vincristine or vinblastine), AB8939 is not deactivated by myeloperoxidase and has been shown to have a strong anti-proliferative effect in refractory/resistant AML cell lines.2 Data on this will be presented at the 61st Annual Meeting and Exposition of the American Society of Hematology which will take place in Orlando, US, on the 7–10th December 2019.
Orphan drug status grants a company with a seven-year exclusivity period for marketing and allows the company to apply for funding for phase I and II clinical trials, providing some financial benefits and a quicker regulatory process further down the line.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What barriers do you encounter when conducting multiple MRD tests during treatment?